What is Foresight Diagnostics?
Foresight Diagnostics operates at the vanguard of cancer diagnostics, specializing in the development of highly sensitive liquid biopsy testing. The company's core technology enables the measurement of minimal residual disease across a broad spectrum of oncological conditions. By providing actionable, high-fidelity data, Foresight Diagnostics empowers physicians and biopharmaceutical partners to transition toward more personalized, data-driven treatment paradigms. This technological edge is critical for improving patient outcomes and optimizing therapeutic efficacy in complex clinical environments.
How much funding has Foresight Diagnostics raised?
Foresight Diagnostics has raised a total of $104.3M across 3 funding rounds:
Series A
$12.5M
Series B
$58.8M
Series B
$33M
Series A (2021): $12.5M with participation from Bluebird Ventures, Pear Ventures, and Civilization Ventures
Series B (2023): $58.8M led by Bluebird Ventures, Foresite Capital, and Pear Ventures
Series B (2024): $33M supported by Civilization Ventures, Agent Capital, Bluebird Ventures, Stanford University, Pear VC, and Foresite Capital
Key Investors in Foresight Diagnostics
Civilization Ventures
A venture capital firm specializing in preventative, personalized, and regenerative healthcare solutions with a strong track record in genomics and diagnostics.
Foresite Capital
A multi-stage investment firm that utilizes a data science-driven approach to transform healthcare by funding breakthrough opportunities at the intersection of technology and biology.
Agent Capital
A specialized healthcare firm focused on novel therapeutics and treatments, collaborating with entrepreneurs to address unmet needs in oncology, neurology, and immunology.
What's next for Foresight Diagnostics?
With this latest infusion of capital, Foresight Diagnostics is poised to accelerate its clinical validation programs and expand its commercial footprint. The company's strategic roadmap focuses on scaling its MRD testing capabilities to meet the increasing demand for precision oncology tools. As the firm moves deeper into its growth phase, it will likely leverage its robust investor network—including specialized health-tech venture firms—to navigate regulatory milestones and forge deeper partnerships within the biopharmaceutical industry, ultimately aiming to set a new standard for sensitivity in cancer monitoring.
See full Foresight Diagnostics company page
